Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro.Processa Pharmaceuticals on Wednesday provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer.Data from the first 16 of 19 patients enrolled indicate that NGC-Cap significantly increases expo ...